162 filings
6-K
GNFT
Genfit
25 Apr 24
Current report (foreign)
4:10pm
6-K
GNFT
Genfit
15 Apr 24
Current report (foreign)
4:10pm
6-K
GNFT
Genfit
5 Apr 24
GENFIT Announces Publication of the 2023 Universal Registration Document and the 2023 Annual Report on Form 20-F
2:03pm
20-F
2023 FY
GNFT
Genfit
Annual report (foreign)
5 Apr 24
11:44am
6-K
GNFT
Genfit
4 Apr 24
GENFIT Reports Full-Year 2023 Financial Results and Provides Corporate Update
4:45pm
6-K
x65vb84j mz9pifycz
29 Feb 24
Current report (foreign)
4:10pm
6-K
qcn8s wc0h
17 Jan 24
GENFIT Announces 2024 Financial Calendar
6:00am
6-K
vmf8zh 6xf71t
11 Jan 24
Current report (foreign)
4:10pm
6-K
ndjsou8
8 Dec 23
Current report (foreign)
8:00am
6-K
h9vk fslhov
7 Dec 23
Ipsen confirms U.S. FDA grants priority review for New Drug Application for elafibranor for the treatment of rare cholestatic liver disease, PBC
6:37am
6-K
anq4by23a scis
6 Dec 23
Current report (foreign)
11:30am
6-K
nv3 hktgctxl6lb
16 Nov 23
GENFIT Highlights ACLF Development Strategy at “ACLF Day” during AASLD The Liver Meeting® 2023
4:10pm
6-K
9e4h17amjucy gf31or
13 Nov 23
Current report (foreign)
4:30pm
6-K
4w3h7c9j3k 2b2
9 Nov 23
GENFIT Reports Third Quarter 2023 Financial Information
4:10pm
6-K
rrwm6nqldb4 tc1b
6 Nov 23
GENFIT to Present Update on Scientific and Corporate Progress at The Liver Meeting® 2023
7:00am
6-K
uh4jqm pv4ja
26 Sep 23
GENFIT Announces Publication in Nature Medicine Confirming the Performance of its NASH Diagnostic Technology
4:10pm
6-K
ihc49s1zjug91 dexw
20 Sep 23
GENFIT Reports First Half-Year 2023 Financial Results and Provides Corporate Update
4:51pm
6-K
mnwoosjyscs
20 Sep 23
Current report (foreign)
4:44pm
6-K
u62me5d70henj 1hs
5 Sep 23
GENFIT to Participate in Upcoming Investor Conferences
4:10pm
6-K
t1kov9di
10 Aug 23
GENFIT Announces the Publication of New Data on the Clinical Performance of NIS2+™ in Older Patients in Hepatology Communications
4:10pm